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Cardiac resynchronization therapy (CRT) is an established adjunctive treatment for patients
with systolic heart failure (HF) and ventricular dyssynchrony. The majority of recipients
respond to CRT with improvements in quality of life, New York Heart Association
functional class, 6-min walk test, and ventricular function. Management of HF after CRT
may include up-titration of neurohormonal blockade and an exercise prescription through
cardiac rehabilitation to further improve and sustain clinical outcomes. Diagnostic data
provided by the CRT device may help to facilitate and optimize treatment. Initial
nonresponder rates remain problematic. We suggest a simple step-by-step management and
troubleshooting strategy that integrates device function with advanced HF therapy in patients
who do not initially respond to CRT. This algorithm represents a new, comprehensive,
collaborative approach between the HF and electrophysiology specialists to further improve
and sustain outcomes in the field of CRT. (J Am Coll Cardiol 2005;46:2193–8) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.078the American College of Cardiology Foundation
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approximately 271,000 heart failure (HF) patients in the
.S. have received cardiac resynchronization therapy (CRT)
ince the Food and Drug Administration approved this
herapy in 2001 for moderate to severe HF (1). Indications
or CRT are based on the American College of Cardiology,
merican Heart Association, and Heart Rhythm Society
uidelines, which recommend CRT for New York Heart
ssociation (NYHA) functional class III or IV HF patients
ho are refractory to pharmacologic therapy and have QRS
urations 130 ms, ejection fractions 35%, and left
entricular (LV) end-diastolic dimensions55 mm (level of
vidence IIA) (2). These guidelines reflect the results of
everal large clinical trials that randomized over 2,500 HF
atients to CRT versus placebo and demonstrated the
enefit of CRT in measurements of functional capacity,
xercise tolerance, ventricular remodeling, and reduction in
ospitalizations and mortality over a six-month period
3–8).
The beneficial effects of CRT have been shown up to 18
onths after device implantation (9). In each of these trials,
nvestigators measured the sole effect of restoring ventricular
ynchrony on clinical outcomes without significant change
n neurohormonal blockade during clinical follow-up. With
From the *Division of Cardiovascular Medicine, College of Medicine, and the
Department of Clinical and Health Psychology, College of Public Health and
ealth Professions, University of Florida Health Science Center, Gainesville, Florida.p
Manuscript received December 22, 2004; revised manuscript received February 23,
005, accepted March 10, 2005.ptimal background medical therapy for HF, about 70% of
atients respond to CRT (10).
How best to manage patients after CRT, specifically
ptimizing medical and other HF therapies, has not been
ystematically studied. Clinical trials evaluating approaches
o the nonresponder and their impact on clinical outcomes
re lacking and badly needed. The purpose of this review is
o describe and expand upon the management of HF
atients after CRT. We discuss optimization and mainte-
ance of pharmacologic therapy along with maintaining
dequate device function to improve and sustain clinical
utcomes.
LINICAL EXPECTATIONS AND MANAGEMENT
fter successful implantation of a CRT device, a series of
linical events can be expected over the next several months.
mmediately after implant, assuming adequate LV lead
osition and thresholds, systolic blood pressure, cardiac
utput, and stroke work usually increase, whereas end-
ystolic volumes and pulmonary capillary wedge pressure
ecrease (11,12). The change in hemodynamic profile is the
esult of immediate correction of ventricular dyssynchrony
esulting in direct improvement of LV systolic dysfunction.
ome patients may feel the effects as early as one month
fter implant though others may require a longer period of
ime for symptom relief (3). The change in hemodynamic
rofile (increased cardiac output, systolic blood pressure,
nd decreased pulmonary capillary wedge pressure) is im-
ortant to recognize because it may require reduction in
d
w
a
p
e
O
m
b
d
l
c
(
a
w
r
b
v
f
s
M
u
p
t
d
o
(
m
b
d
b
o
C
s
p
w
f
o
f
a
(
C
i
p
t
A
t
v
f
r
m
I
v
t
r
c
b
C
d
c
a
p
a
a
p
a
t
d
i
v
C
a
P
C
t
R
T
C
f
i
H
d
i
p
t
w
o
w
i
h
n
a
b
m
C
i
1
u
o
2194 Aranda, Jr. et al. JACC Vol. 46, No. 12, 2005
Algorithm for Treatment of Heart Failure After CRT December 20, 2005:2193–8iuretic dose. From our clinical experience, if a HF patient
ith near optimal filling pressures receives CRT and has
dequate diuresis, failure to reduce diuretics will result in
rerenal azotemia which may mask or delay the beneficial
ffects of CRT.
ptimization of neurohormonal blockade. Beta-blockers
ay also be increased after CRT. Pharmacologic therapy with
eta-blockers has dramatically reduced HF mortality, sudden
eath, and hospitalizations (13–15). Despite these estab-
ished benefits, use of beta-blockers in recent randomized
linical HF trials is somewhere between 30% and 62%
3,16). Many physicians hesitate starting beta-blocker ther-
py or increasing beta-blocker dose because of potential
orsening HF, hypotension, and bradycardia (17). Cardiac
esynchronization therapy improves HF symptoms and
lood pressure while restoring synchrony by pacing both
entricles (3,7,11). Therefore, some of the clinical problems
or which beta-blocker therapy is abandoned or not aggres-
ively pursued are stabilized with CRT. The Comparison of
edical Therapy, Pacing, and Defibrillation in Heart Fail-
re (COMPANION) trial demonstrated that systolic blood
ressure increases with CRT and that outcomes of hospi-
alization and mortality were better with CRT or CRT and
efibrillator with concomitant beta-blocker therapy (7).
There are several small retrospective analyses that dem-
nstrate that beta-blocker dose can be increased after CRT
18,19). This is an important observation because approxi-
ately 33% to 45% of HF patients in clinical trials of
eta-blockers did not achieve maximum target beta-blocker
oses (13,17). Furthermore, we have demonstrated that
eta-blocker therapy can be re-initiated after CRT in 50%
f patients with a history of intolerance to this therapy (19).
ardiac resynchronization therapy is not a replacement for
tandard pharmacologic therapy, but it may offer the op-
ortunity to augment neurohormonal blockade in patients
ho have ventricular dyssynchrony and current indications
or this device. This combination of device therapy and
ptimal medical management may provide synergistic ef-
ects regarding reverse LV remodeling, improved systolic
nd diastolic function, and increased long-term survival
20–23).
ardiac rehabilitation after CRT. Because improvement
n functional capacity can be derived from CRT, an exercise
rescription through cardiac rehabilitation may further ex-
end benefits, as noted in other HF populations (24).
lthough there is a lack of randomized controlled data in
Abbreviations and Acronyms
AV  atrioventricular
CRT  cardiac resynchronization therapy
HF  heart failure
LV  left ventricular
NYHA  New York Heart Association
VV  interventricularhe CRT patient (25), the improvements in function pro- mided by CRT may allow a therapeutic opportunity to
urther increase patients’ functional capacity by cardiac
ehabilitation. Although validation of these observations
ust await completion of the National Heart Lung Blood
nstitute-sponsored Heart Failure-A Controlled Trial In-
estigating Outcomes of Exercise Training (HF-Action),
hese patients may derive additional benefit by continuing to
everse the spiral of functional disability that is often a
ombination of reduced cardiac function and sedentary
ehaviors.
RT diagnostics for HF management. Advancement of
iagnostics in CRT devices allows clinicians to improve patient
are by moving beyond device management to patient man-
gement utilities. Devices now have the potential to provide
atient-specific clinical information that is useful in the man-
gement of heart failure. Trending data such as episodes of
trial fibrillation, ventricular rates during atrial fibrillation,
atient activity, and heart rate variability may be used to
ssess progression of heart failure and efficacy of HF
herapies. Decreased heart rate variability is a predictor of
eath due to progressive heart failure and can be effectively
mproved by CRT (26,27). Improvement in heart rate
ariability may be a useful indicator that can be followed by
RT diagnostic information to assess favorable cardiac
utonomic profiles and that can affect long-term outcomes.
rospective validated data will be needed to determine how
RT diagnostics can be used and whether or not it can lead
o changes in treatment that improve clinical outcomes.
ESPONDER RATES AND
ROUBLESHOOTING CRT DEVICES
linical trials of CRT have demonstrated improvement in
unctional class, ventricular function, and reverse remodel-
ng while reducing hospitalizations and mortality (3–7,20).
owever, 30% of patients undergoing CRT appear to
erive no benefit from this therapy. This nonresponder rate
s derived from several clinical trials in which 30% to 35% of
atients showed either no improvement or worsening symp-
oms after six months of CRT (3,5).
There is no clear consensus or standardized definition of
hat is considered to be an adequate response to this therapy
r when a patient should be considered a nonresponder. Some
ould consider improvement in NYHA functional class or
ncreased distance walked in 6 min as an adequate response;
owever, these improvements may be influenced by sponta-
eous changes as well as by a placebo effect. Indeed, Mehra
nd Greenberg (28) have suggested that the magnitude of
enefit attributable to a surgical device should be deter-
ined by evaluating its placebo-subtracted efficacy. For
RT, their analysis indicates that the placebo-subtracted
mprovement in NYHA functional class is in the realm of
5% to 30% (28). Others would consider changes in oxygen
ptake at anaerobic threshold during exercise or reduction
f LV systolic and diastolic volumes along with improve-
ent in functional class as an adequate response.
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December 20, 2005:2193–8 Algorithm for Treatment of Heart Failure After CRTBased on current CRT data, we believe that re-evaluation
f a CRT device should be considered if there is no
mprovement in symptoms after six months of CRT or
here is worsening heart failure with increased ventricular
emodeling within the first several months after initiation of
RT. Figure 1 represents a potential troubleshooting algo-
ithm for HF patients who are not responding to CRT.
his algorithm may or may not improve clinical outcomes
nd has not been prospectively validated. It does suggest a
trategy to manage common problems found in this heart
ailure population, and it combines that strategy with
dequate device optimization and function.
linical problem solving. A CRT nonresponder should
nitially be evaluated for prerenal azotemia, development of
trial fibrillation, or cardiac ischemia (in a patient with
oronary heart disease). Failure to reduce diuretics in a
atient with a functioning CRT device who has achieved
ptimal filling pressure may result in symptoms that mask
he effects of CRT. Rate control up to and including AV
ode ablation or electrical cardioversion to restore normal
igure 1. Troubleshooting algorithm for heart failure patients with wors-
ning symptoms, progressive ventricular remodeling, or no improvement in
ew York Heart Association functional class despite one to six months of
ardiac resynchronization therapy (CRT). AV  atrioventricular; CXR 
hest X-ray; EKG electrocardiogram; Htx heart transplant; LV left
entricular; LVAD  left ventricular assist device; MR  mitral regurgi-
ation; RV right ventricular; VV interventricular. *Cardiac ischemia is
valuated in patients with ischemic cardiomyopathy. **Evidence of dyssyn-
hrony includes septal to posterior wall motion delay 130 ms, intraven-
ricular mechanical delay 40 ms, and tissue Doppler imaging 65 ms.inus rhythm will be necessary in patients who develop atrial Abrillation. Permanent atrial fibrillation in a heart failure
atient with CRT will require that the device be repro-
rammed from the DDDR to the VVIR mode in order to
revent tracking of the atria, leading to a rapid ventricular
esponse, and to save battery life. Although one would
ssume that all attempts at complete revascularization have
een pursued in a patient with ischemic cardiomyopathy
rior to considering CRT, cardiac ischemia should be
eevaluated in a patient not responding to this therapy.
evice interrogation. Absence of prerenal azotemia, atrial
brillation, or cardiac ischemia in a CRT nonresponder
hould be followed by evaluation and interrogation of the
RT device. Six percent of patients may have LV lead
islodgement during long-term pacing, leading to loss of
V capture (3). Loss of right ventricular (RV) capture also
ust be evaluated. Comparison of a current electrocardio-
ram and chest x-ray with a baseline electrocardiogram and
hest x-ray from the time of implant may be a simple
creening procedure to detect loss of RV or LV capture.
art et al. evaluated the surface electrocardiographic mor-
hology changes during RV, LV, and BiV pacing in the
ost AV Node Ablation Evaluation (PAVE) study popu-
ation (29). Increment of R-wave and diminution of S-wave
mplitude in lead II and/or no change in bundle branch
orphology in V1 was associated with loss of RV capture
positive predictive value 93%, negative predictive value
3%). Deepening of S-wave in lead II and/or no change in
undle branch morphology in V1 was associated with loss of
V capture (positive predictive value 71%, negative predic-
ive value 89%). Thus, it may be useful to have a baseline
lectrocardiogram from the time of implant readily available
or comparison with future electrocardiograms to evaluate
ight and left ventricular capture. This can be confirmed
ith interrogation of the device.
trioventricular (AV)/interventricular (VV) delay opti-
ization. Adequate device function in a CRT patient with
ersistent or worsening symptoms should lead to evaluation
f AV and VV delay (if available). Restoration of optimal
V timing may improve systolic performance by optimizing
V preload. In one study, the effect of the AV interval on
p/dt during biventricular pacing or LV free wall pacing was
inimal except when it declined to90 ms (30). In another
tudy, enhancement of dp/dt was observed at AV intervals
etween 100 and 160 ms with a maximum at 125 ms (31).
ven though AV delay has less influence on LV function
han CRT pacing site, it should be optimized according to
itral Doppler inflow pattern in someone who is not
esponding to CRT. An increase in the aortic velocity time
ntegral and a prolongation of the diastolic filling time at the
itral valve by at least 10% to 20% from baseline indicates
ystolic improvement (32). Kindermann et al. (33) have
roposed that the optimal AV delay should provide the
ongest LV filling time without premature truncation of the
wave by mitral valve closure. Variations of this method
ave been applied more recently to CRT (34). The sensed
V-delay is programmed to approximately 75% of the PR
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Algorithm for Treatment of Heart Failure After CRT December 20, 2005:2193–8nterval to ensure complete ventricular pacing. Pulsed-wave
oppler is performed at the tips of the mitral leaflets in the
pical four-chamber view to obtain transmitral flow. E and
waves are recorded and the AV delay is shortened by 20 ms
ntil the A-wave is truncated. The truncated A-wave repre-
ents early mitral valve closure during ventricular systole. The
V delay is then lengthened by 10 ms until the A-wave is no
onger truncated. At this point ventricular contraction should
egin just at the end of atrial contraction. There is much
iscussion regarding the clinical utility of this intervention.
he fact that patients with atrial fibrillation and AV node
blation may benefit from CRT suggests that AV interval
ettings are of less importance in CRT (35). Nevertheless,
V delay should be evaluated in a nonresponder.
There are recent data on VV interval optimization during
RT. During normal electrical activation in patients with
ormal QRS durations, the delay between RV and LV
ontraction is about 6 ms (36). New-generation CRT
evices allow for optimization of VV delay which, in
reliminary studies, has resulted in short-term improvement
n hemodynamic measurements of ejection fraction, cardiac
utput, and increased LV filling times as compared to
imultaneous ventricular pacing (37,38). There are no data
n long-term clinical outcomes after VV optimization. The
ptimal VV interval may vary according to etiology of HF.
n one study, the optimum VV interval as determined by
ncrease in LV dp/dt in patients with sinus rhythm was 52 
1 ms for ischemic cardiomyopathy, 28  30 ms for
diopathic dilated cardiomyopathy, and 37  32 ms for
atients with atrial fibrillation (39). Patients with ischemic
ardiomyopathy may require longer VV intervals necessitat-
ng more pre-excitation of the left ventricle due to the
resence of scar tissue resulting in a slower conduction
elocity (40).
The optimal pacing sequence may be difficult to predict
etween patients. In some individuals, CRT with LV
re-activation results in significant cardiac output increase,
hereas in other patients improvements have been seen
ith RV pre-activation as compared to simultaneous CRT
38). The optimal VV interval and sequence of ventricular
re-excitation can be determined by LV filling time as
etermined by pulsed-wave Doppler transmitral flow (time
etween onset E wave and the end of the A-wave), cardiac
utput determined by the LV outflow method, and aortic
elocity time integral (38,41). The effects of AV and VV
ptimization on hemodynamics and ventricular function are
mmediate (31,38). If inappropriate AV or VV delay is
esponsible for a lack of response to CRT, optimization of
hese intervals should translate into improvement of symp-
oms within a short period of time.
chocardiographic dyssynchrony studies. If there is no
mprovement in symptoms after device optimization, then
oninvasive echocardiographic dyssynchrony studies should
e considered. There are several studies suggesting that the
resence of interventricular or intraventricular dyssynchrony
etected by a different echocardiographic technique prior to sRT implant is the best predictor of improvement of LV
unction and reverse remodeling after CRT (42–46). Spe-
ifically, septal to posterior wall motion delay 130 ms as
easured by M-mode echocardiography at the level of
apillary muscle (42), interventricular mechanical delay 
0 ms defined as the time difference between LV and RV
re-ejection intervals (43), and interventricular dyssynchrony
65 ms as detected by tissue Doppler imaging (44) are
ignificant measurements of dyssynchrony and predict response
o CRT. After successful CRT there should be minimal
nterventricular or intraventricular dyssynchrony. Yu et al.
47), using tissue Doppler imaging, showed complete reso-
ution of interventricular dyssynchrony after CRT. Pitzalis
t al. (42) report substantial reduction of intraventricular
yssynchrony with a significant reduction of septal to
osterior wall motion delay. If significant interventricular or
ntraventricular dyssynchrony is still present in a CRT
onresponder, then lead position or revision should be
onsidered through transvenous or epicardial lead place-
ent. The implanter should attempt to pace the most
elayed sites of the left ventricle as detected by echocardi-
graphy to maximize the effect of CRT. Optimal resyn-
hronization in the region with the latest activity detected
hrough echocardiographic parameters leads to improved
linical response in CRT patients (48).
valuation of mitral regurgitation. Persistent symptoms
espite correction of ventricular dyssynchrony should be
ollowed by evaluation for significant mitral regurgitation.
auses of functional mitral regurgitation (MR) in dilated
ardiomyopathy range from ventricular dilation with in-
reasing distance between papillary muscles and the en-
arged mitral annulus restricting leaflet motion, to delayed
ctivation of the posteromedial papillary muscle resulting
rom ventricular dyssynchrony. Functional MR is reduced
y CRT (49). Persistent MR despite correction of ventric-
lar dyssynchrony may mask the effects of CRT. Recent
tudies have shown that mitral valve surgery offers symp-
omatic improvement to MR patients with poor LV function
50,51). In selected patients, mitral valve surgery should be
onsidered to correct persistent significant MR in a CRT
onresponder.
An HF patient with CRT who persists with symptoms
espite adequate device function and absence of dyssyn-
hrony or significant MR should be considered a true
onresponder. Most patients studied in CRT clinical trials
ave NYHA functional class III heart failure. There is a
rowing enthusiasm for the use of cardiac support devices in
his patient population, including CRT nonresponders
52,53). In selected nonresponders who progress to NYHA
unctional class IV heart failure, the use of LV assist devices
r cardiac transplantation should be considered (54,55).
ONCLUSIONS
ardiac resynchronization therapy is now considered for
evere heart failure refractory to pharmacologic therapy in
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December 20, 2005:2193–8 Algorithm for Treatment of Heart Failure After CRTatients with prolonged QRS intervals. As the number of
atients receiving CRT continues to grow, a new, more
niform approach between heart failure and electrophysiol-
gy specialists will be needed to maintain and improve
linical results that are achievable through this therapy (56).
his standardized approach will need to address issues of
atient selection, changes in pharmacologic therapy after
RT, and maintenance of adequate CRT device function.
t is the combination of these three factors that will further
mprove outcomes in the field of CRT.
eprint requests and correspondence: Dr. Juan M. Aranda, Jr.,
600 SW Archer Road, Room M421, Gainesville, Florida 32610.
-mail: arandjm@medicine.ufl.edu.
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